1.To describe advancements in molecularly targeted therapies for cancer, including novel inhibitor of Glycogen synthase kinase 3 beta.
2.To define the evolving field of novel combinations of immunotherapy drugs and biomarkers for tumor response.
01/25/2019 - 8:00am to 9:00am CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Benedito Carneiro, MD